Drugs / DNP002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06466265 | May 2021 → Dec 2024 | — | Kumho HT Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNP002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06466265 ↗ |
| Route | Intravenous | “receive escalating doses of DNP002 intravenously” NCT06466265 ↗ |